FANCB and acute myeloid leukemia: FAB subtype was shown to affect survival outcomes among the children with AML, with patients having FAB-M2 (3.0 months) showing better overall survival profiles than those having either FAB-M0 (0.6 months) or FAB-M7 (0.3 months).